Page 6 - Expanded Access Program News Today

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

(RTTNews) - The U.S. Food and Drug Administration approved HEPZATO KIT (melphalan/Hepatic Delivery System) as a liver-directed treatment for adult...

The Hepzato Kit is a direct-to-liver therapy for patients with uveal melanoma with hepatic metastases.

The FDA approved Delcath Systems Inc's (NASDAQ: DCTH) HEPZATO KIT (melphalan/Hepatic Delivery System). 

- Seelos expects to release top-line data in its registration directed study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation ...

Highlights Cohort 2 of the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has been...

FDA indicated that approval of MAT2203 as a first-line treatment for invasive aspergillosis will require an adequately powered study with an active control group and an all-cause mortality...

RUCONEST® business performed strongly in 2Q 2023; continue to anticipate low single digit annual revenue growth Strong start to U.S. Joenja® launch during 2Q...

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that RHB-107 (upamostat)3 has been accepted for inclusion in the Austere environments Consortium for Enhanced Sepsis Outcomes' (ACESO) U.S. Government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment to be conducted in the U.S., Thailand, Ivory Coast and South Africa. The Company also announced that the Phase 2 s...

/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has closed...